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Background: Optical coherance tomography (OCT) studies have demonstrated delayed neointimal coverage following drug-eluting stent (DES) 
implantation. While newer DESs promote more favorable vascular healing, the clinical implications are still under-investigating. The advantages 
that Zotarolimus-eluting stent (ZES) is coated with highly biocompatible polymer and biolimus-eluting stent (BES) has biodegradable polymer 
might provide clinical studies showing that both stents are quite safe as well as efficacious. This study is objected to investigate 6month neointimal 
coverage of these 2nd generation DES.
methods: Significant coronary artery stenosis amenable for coronary revascularization with single stent (diameter of 2.75-4.0 mm and length of 
≤ 30mm) were enrolled. Patients with acute ST elevation MI were excluded. 60 consecutive patients were randomly assigned to BES (n=30) versus 
ZES (n=30). Angiographic follow-up and time-domain OCT imaging with motorized pull-back at 1 mm/s was performed at six months after study stent 
implantation in all patients. OCT endpoints are endothelial coverage failure, expressed as % of struts without coverage, and neoinitimal hyperplasia (NIH).
results: Baseline clinical characteristics were different in both groups. During follow up, there were no clinical events including myocardial 
infarction, stroke, or target vessel failure. Angiographic follow up data were not significantly different. Stent diameter (mm) in BES and ZES were 
3.44±0.47, 3.31±0.42, respectively (p=0.283). Stent length (mm) in BES and ZES were 17.4±4.2, 17.8±4.3 (p=0.673). Late loss (mm) was 
0.13±0.25, 0.18±0.28 (p=0.541). OCT follow up data also were not significantly different. Uncovered strut (%) in BES and ZES were 20.5±21.8, 
17.7±22.4, respectively (p=0.625). Mean NIH (mm2) in BES and ZES were 0.38±0.28, 0.45±0.32 (p=0.409). Intra-stent thrombi were not noticed in 
both groups.
conclusions: The cumulative OCT and angiographic results in both ZES and BES were not significantly different. BES with biodegradable polymer 
has comparable angiographic and OCT outcome with ZES with durable polymer. Further data would be needed for this conclusion.
